Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program
2018
PurposeEvidence-based guidelines inform treatment decisions for patients for whom germline genetic information is available. Our real-time tumor sequencing program, which makes precision treatment decisions for patients with cancer, produces matched germline information, providing a unique opportunity to efficiently implement pharmacogenetics and benefit patients.MethodsThe germline genetic database from the Michigan Oncology Sequencing (MI-Oncoseq) program was searched for 21 clinically actionable polymorphisms in five cancer-relevant genes: TPMT, DPYD, CYP2C19, CYP3A5, and UGT1A1. Residual germline DNA was sent to an external Clinical Laboratory Improvement Amendments–approved laboratory for confirmatory genotyping. The medical records of MI-Oncoseq patients with actionable phenotypes were searched for receipt of relevant drugs and to determine whether having genetic information at the time of treatment would have led to a treatment recommendation.ResultsAll nine variants in TPMT, DPYD, and CYP2C19 that...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
6
Citations
NaN
KQI